Michael M Hoffmann1,2. 1. Institute of Clinical Chemistry and Laboratory Medicine, Medical Center - University of Freiburg, Hugstetter Straße 55, D-79106, Freiburg, Germany. michael.marcus.hoffmann@uniklinik-freiburg.de. 2. Faculty of Medicine, University of Freiburg, Freiburg, Germany. michael.marcus.hoffmann@uniklinik-freiburg.de.
Abstract
PURPOSE OF REVIEW: Today, statins are the first choice to lower LDL cholesterol and concomitantly the risk of atherosclerotic cardiovascular disease. There is a significant minority of statin-treated patients who are more susceptible to occasionally serious side effects that may increase morbidity and lead to compliance problems or the discontinuation of therapy. This review addresses the question of whether genetics can provide meaningful insights into the risk of statin side effects or therapy success. RECENT FINDINGS: The use of genome-wide association studies has significantly reduced the number of predictive genetic markers for statin effects, and the isolated effect of the surviving markers is low; more promising are approaches to stratify patients with genetic risk scores. Patients reveal a pronounced individual response to the administration of statins. The idea of being able to adequately describe this variability with single genetic markers has failed, genetic risk scores will be the method of choice.
PURPOSE OF REVIEW: Today, statins are the first choice to lower LDL cholesterol and concomitantly the risk of atherosclerotic cardiovascular disease. There is a significant minority of statin-treated patients who are more susceptible to occasionally serious side effects that may increase morbidity and lead to compliance problems or the discontinuation of therapy. This review addresses the question of whether genetics can provide meaningful insights into the risk of statin side effects or therapy success. RECENT FINDINGS: The use of genome-wide association studies has significantly reduced the number of predictive genetic markers for statin effects, and the isolated effect of the surviving markers is low; more promising are approaches to stratify patients with genetic risk scores. Patients reveal a pronounced individual response to the administration of statins. The idea of being able to adequately describe this variability with single genetic markers has failed, genetic risk scores will be the method of choice.
Authors: Paul S Jellinger; Yehuda Handelsman; Paul D Rosenblit; Zachary T Bloomgarden; Vivian A Fonseca; Alan J Garber; George Grunberger; Chris K Guerin; David S H Bell; Jeffrey I Mechanick; Rachel Pessah-Pollack; Kathleen Wyne; Donald Smith; Eliot A Brinton; Sergio Fazio; Michael Davidson Journal: Endocr Pract Date: 2017-04 Impact factor: 3.443
Authors: Massimo F Piepoli; Arno W Hoes; Stefan Agewall; Christian Albus; Carlos Brotons; Alberico L Catapano; Marie-Therese Cooney; Ugo Corrà; Bernard Cosyns; Christi Deaton; Ian Graham; Michael Stephen Hall; F D Richard Hobbs; Maja-Lisa Løchen; Herbert Löllgen; Pedro Marques-Vidal; Joep Perk; Eva Prescott; Josep Redon; Dimitrios J Richter; Naveed Sattar; Yvo Smulders; Monica Tiberi; H Bart van der Worp; Ineke van Dis; W M Monique Verschuren; Simone Binno Journal: Eur Heart J Date: 2016-05-23 Impact factor: 29.983
Authors: J L Mega; N O Stitziel; S Kathiresan; M S Sabatine; J G Smith; D I Chasman; M Caulfield; J J Devlin; F Nordio; C Hyde; C P Cannon; F Sacks; N Poulter; P Sever; P M Ridker; E Braunwald; O Melander Journal: Lancet Date: 2015-03-04 Impact factor: 79.321
Authors: Brian A Ference; Jennifer G Robinson; Robert D Brook; Alberico L Catapano; M John Chapman; David R Neff; Szilard Voros; Robert P Giugliano; George Davey Smith; Sergio Fazio; Marc S Sabatine Journal: N Engl J Med Date: 2016-12-01 Impact factor: 91.245
Authors: Jemma C Hopewell; Sarah Parish; Alison Offer; Emma Link; Robert Clarke; Mark Lathrop; Jane Armitage; Rory Collins Journal: Eur Heart J Date: 2012-10-24 Impact factor: 29.983
Authors: Moneeza K Siddiqui; Cyrielle Maroteau; Abirami Veluchamy; Aleksi Tornio; Roger Tavendale; Fiona Carr; Ngu-Uma Abelega; Dan Carr; Katyrzyna Bloch; Par Hallberg; Qun-Ying Yue; Ewan R Pearson; Helen M Colhoun; Andrew D Morris; Eleanor Dow; Jacob George; Munir Pirmohamed; Paul M Ridker; Alex S F Doney; Ana Alfirevic; Mia Wadelius; Anke-Hilse Maitland-van der Zee; Daniel I Chasman; Colin N A Palmer Journal: Eur Heart J Date: 2017-12-21 Impact factor: 35.855